Presentation

Company Profile
Arctic Bioscience is a biotechnology company that develops, manufactures, and sells products based on bioactive herring roe compounds. The company has a clinical pharmaceutical business unit and a commercial nutraceutical business unit, both built upon their proprietary platform technology.

Recent highlights
In 2020, the company announced that the results for the first clinical trial of their lead asset, HRO350 had been published in ActaDV. This was a randomised, double-blind, placebo-controlled study assessing the safety and efficacy of HRO350 in 64 patients with plaque psoriasis. The results showed a statistically significant improvement in the mean PASI scores of the treatment group compared to placebo at week 26. The company announced in early March 2021 that they signed a 3-year agreement worth NOK 75 million with Smerud Medical Research International, to conduct a phase IIb clinical study on psoriasis. The purpose of the study is to investigate the efficacy and safety of HRO350 and to establish the optimal dose. The study will include more than 500 patients and is planned to be conducted in seven countries, including Norway.

Outlook
The Phase IIb study is the predominant focus of the company. Recruitment of patients is planned to start in H1 2022, with a projected 6-month inclusion time and 6-month data read-out in mid-2023. At the same time, the company is expanding their nutraceutical business with B2B and B2C sales and a strategic partnership in China.